IntriCon Acquires Emerald Medical Services

Rhea-AI Summary

IntriCon Corporation (NASDAQ: IIN) has completed the acquisition of Emerald Medical Services (EMS) for approximately $7.1 million, alongside 80,000 shares of common stock and potential cash earnouts based on sales milestones. This strategic acquisition enhances IntriCon's manufacturing capabilities in surgical navigation and facilitates entry into high-growth medical markets, particularly with complex interventional catheters. The deal is expected to be accretive to revenue and earnings in 2020, thus diversifying IntriCon's customer base and expanding its market potential.

Positive

• Acquisition enhances manufacturing capabilities in surgical navigation.
• Provides access to high-growth medical markets with complex catheters.
• Expected to be accretive to revenue and earnings in 2020.
• Diversifies customer base, enhancing market reach.

Negative

• None.

• Synergistic joint development and manufacturing capability expands market opportunity in surgical navigation
• Provides immediate access to technology platform serving new high growth medical end-markets with complex interventional catheters  
• Accretive transaction delivers long-term revenue growth potential and diversifies customer base

ARDEN HILLS, Minn., May 19, 2020 (GLOBE NEWSWIRE) -- IntriCon Corporation (NASDAQ: IIN), a designer, developer and manufacturer of miniature interventional, implantable and body-worn medical devices, today announced that it has completed the acquisition  of privately held Emerald Medical Services (EMS) Pte Ltd. The acquisition expands IntriCon’s medical coil and micro-miniature medical device engineering and manufacturing capabilities in surgical navigation and accelerates diversification into potential new end markets.

Emerald Medical Services, based in Singapore, provides joint engineering and manufacturing services for complex medical devices, including catheters covering a range of applications for cardiology, peripheral vascular, neurology, radiology and pulmonology. EMS’s production capability consists of design, development, manufacturing, testing and non-sterile packaging services.

Under the terms agreement to acquire EMS, the transaction consideration consists of an upfront payment of approximately $7.1 million, 80,000 shares of IntriCon common stock, and a cash earnout based on the achievement of specific sales milestones over a three-year period.

“As we sought opportunities to build on our core competencies as a miniature and micro-miniature device manufacturer, Emerald Medical Services stood out as an ideal strategic complement to our business,” said Mark Gorder, president and chief executive officer of IntriCon. “We have been familiar with their high-quality design, development and manufacturing services in the complex catheter space for some time. In addition, EMS’s existing technology expands our addressable market within surgical navigation and diversifies our customer base. This transaction combines two business that are dedicated to developing and manufacturing devices that support the advancement of medical technology,” concluded Gorder.

“Emerald has made significant investments in developing a portfolio of industry leading technologies and establishing a global low-cost manufacturing footprint, which makes our business synergistic with IntriCon’s strategic growth objectives,” said Steve Wiesner, chief executive officer of EMS. “We look forward to joining IntriCon at this pivotal time and to becoming a material contributor to the opportunity ahead.”

IntriCon expects the acquisition to be accretive to revenue and earnings in 2020.

About IntriCon Corporation
Headquartered in Arden Hills, Minn., IntriCon Corporation designs, develops and manufactures miniature interventional, implantable and body-worn medical devices. These advanced products help medical, healthcare and professional communications companies meet the rising demand for smaller, more intelligent and better connected devices. IntriCon has facilities in the United States, Asia and Europe. The company’s common stock trades under the symbol “IIN” on the NASDAQ Global Market. For more information about IntriCon, visit www.intricon.com.

About Emerald Medical Services

Founded in 2011, Emerald Medical Services Pte Ltd (“EMS”) is a Singaporean limited liability company that provides joint development manufacturing services to medical device original equipment manufacturers (“OEMs”) with a particular focus on advanced complex catheters for cardiology, peripheral vascular, neurology, radiology and pulmonology applications.

Investor Relations Contact:
Leigh Salvo
(415) 937-5404
investorrelations@intricon.com

FAQ

What is the purpose of IntriCon's acquisition of Emerald Medical Services?

The acquisition aims to enhance IntriCon's manufacturing capabilities in surgical navigation and facilitate entry into high-growth medical markets.

What was the transaction value for IntriCon's acquisition of EMS?

IntriCon acquired EMS for approximately $7.1 million, along with 80,000 shares of common stock.

How will the acquisition of EMS impact IntriCon's revenue?

The acquisition is expected to be accretive to both revenue and earnings in 2020.

How does the acquisition diversify IntriCon's business?

The acquisition diversifies IntriCon's customer base and expands its market potential in the surgical navigation sector.

What applications does Emerald Medical Services specialize in?

Emerald Medical Services specializes in advanced complex catheters for applications in cardiology, peripheral vascular, neurology, radiology, and pulmonology.